Thérapeutique Knight réalise le placement par prise ferme d'actions ordinaires précédemment annoncé, y compris l'exercice de l'option de surallocation, pour 230 millions de dollars
02 juin 2016 08h17 HE
|
Thérapeutique Knight Inc.
MONTRÉAL, CANADA--(Marketwired - 2 juin 2016) -
LE PRÉSENT COMMUNIQUÉ EST CENSÉ ÊTRE DIFFUSÉ AU CANADA UNIQUEMENT. IL NE DOIT PAS ÊTRE REMIS...
Knight Therapeutics Completes Previously Announced Bought Deal of Common Shares, Including Exercise of Over-Allotment Option, for $230 million
02 juin 2016 08h16 HE
|
Knight Therapeutics Inc.
MONTREAL, CANADA--(Marketwired - June 2, 2016) -
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR...
Knight to Present at Both the National Bank Financial Quebec Conference in Montreal and the Jefferies Healthcare Conference in New York City
31 mai 2016 08h00 HE
|
Knight Therapeutics Inc.
MONTREAL, QUEBEC--(Marketwired - May 31, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross...
Knight publie ses résultats du premier trimestre 2016
10 mai 2016 06h00 HE
|
Thérapeutique Knight Inc.
MONTRÉAL, CANADA--(Marketwired - 10 mai 2016) - Thérapeutique Knight inc. (TSX:GUD) (« Knight » ou la « Société »),...
Knight Reports First Quarter 2016 Results
10 mai 2016 06h00 HE
|
Knight Therapeutics Inc.
MONTREAL, CANADA--(Marketwired - May 10, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"), a leading Canadian specialty pharmaceutical company, today reported...
Knight Blooms at Healthcare Investor Conference in Toronto
25 avr. 2016 08h00 HE
|
Knight Therapeutics Inc.
MONTREAL, QUEBEC--(Marketwired - April 25, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Mr. Jonathan...
Knight reçoit un ADI de Santé Canada à propos d'ATryn(R)
25 avr. 2016 08h00 HE
|
Thérapeutique Knight Inc.
MONTRÉAL, QUÉBEC--(Marketwired - 25 avril 2016) - Thérapeutique Knight inc. (TSX:GUD) (« Knight »), société pharmaceutique...
Knight Receives NOD from Health Canada for ATryn(R)
25 avr. 2016 08h00 HE
|
Knight Therapeutics Inc.
MONTREAL, QUEBEC--(Marketwired - April 25, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, today announced that it has received...
Knight trouve un partenaire EMPAthique au Moyen-Orient pour Neuragen(R)
25 avr. 2016 08h00 HE
|
Thérapeutique Knight Inc.
MONTRÉAL, QUÉBEC--(Marketwired - 25 avril 2016) - Thérapeutique Knight inc. (TSX:GUD), par le biais de l'une de ses filiales en propriété exclusive...
Knight Finds EMPAthetic Partner for Neuragen(R) in the Middle East
25 avr. 2016 08h00 HE
|
Knight Therapeutics Inc.
MONTREAL, QUEBEC--(Marketwired - April 25, 2016) - Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries ("Knight"), announced today that it has entered into an...